RT Journal Article
SR Electronic
T1 CyclOps: Cyclical development towards operationalizing ML models for health
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.02.22283021
DO 10.1101/2022.12.02.22283021
A1 Krishnan, Amrit
A1 Subasri, Vallijah
A1 McKeen, Kaden
A1 Kore, Ali
A1 Ogidi, Franklin
A1 Alinoori, Mahshid
A1 Lalani, Nadim
A1 Dhalla, Azra
A1 Verma, Amol
A1 Razak, Fahad
A1 Pandya, Deval
A1 Dolatabadi, Elham
YR 2022
UL http://medrxiv.org/content/early/2022/12/08/2022.12.02.22283021.abstract
AB Open source software that enable research and development of machine learning (ML) models for clinical use cases are fragmented, poorly maintained and fall short in functionality. CyclOps is a software framework designed to address this gap and help accelerate the development of ML models for health. In this paper, we describe the architecture, APIs and implementation details of CyclOps, while providing benchmarks on example clinical use cases. We emphasize that CyclOps is developed to be researcher friendly, while providing APIs for building end-to-end pipelines for model development as well as deployment. We adopt software engineering and ML operations (MLOps) best practices, while providing support for handling large volumes of health data. The design of the framework is centered around the notion of iterative and cyclical development of the overall ML system, which consists of data, model development and monitoring pipelines. The core CyclOps package can be installed through the Python Package Index (PyPI) and the source code is available at https://github.com/VectorInstitute/cyclops.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Vector Institute, in collaboration with the GEMINI initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics board approval was obtained from the University Health Network (Toronto), Sunnybrook Health Sciences Centre (Toronto) and St. Michael's Hospital (Toronto) through the integrated Clinical Trials Ontario platform, with St. Michael's Hospital as the Board of Record (CTO project ID: 1394). Research ethics board approval was also obtained from Trillium Health Partners (Mississauga; REB# 742) and Mount Sinai Hospital (Toronto; REB# 15-0075-C).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors, subject to governance policies of datasets used for the experiments. https://www.geminimedicine.ca/ https://physionet.org/content/mimiciv/2.1/